Ophthalmiatrion Eye Hospital of Athens, Athens, Greece.
Can J Ophthalmol. 2011 Dec;46(6):486-90. doi: 10.1016/j.jcjo.2011.09.014.
To evaluate the recurrence of macular edema (ME) in a mixed group of patients with branch (BRVO) and central (CRVO) retinal vein occlusion after early onset treatment with intravitreal injections of ranibizumab.
Nonrandomized, uncontrolled prospective clinical trial.
Forty patients were enrolled in our study. Twenty-two patients had BRVO and 18 patients had CRVO.
All patients had a minimum follow-up of 12 months. All patients had fundus fluorescein angiography (FFA) and optical coherence tomography (OCT) at presentation. The time period between RVO occurrences and initial examination and treatment was <1 month. Every patient was treated with 2 consecutive intravitreal injections of ranibizumab (0.5 mg) 1 month apart. Assessment was carried out on a monthly basis and injection was carried out if necessary, based on OCT findings.
Recurrence of ME occurred in 13 patients (13/22, 59%) in the BRVO group, whereas in the CRVO group occurred in all patients (18/18, 100%). Mean time interval of these recurrences from last injection was 2.4 months and 1.2 months for BRVO and CRVO groups, respectively. Mean period of ME reabsorption was 2.5 months for the BRVO group and 3.5 months for the CRVO group.
Recurrent ME occurred in 77.5% of our patients. These recurrences occurred sooner, were more prominent and lasted longer in patients with CRVO.
评估早期接受玻璃体内雷珠单抗注射治疗的视网膜分支静脉阻塞（BRVO）和视网膜中央静脉阻塞（CRVO）混合患者中黄斑水肿（ME）的复发情况。
非随机、非对照的前瞻性临床试验。
共有 40 名患者入组本研究。22 名患者患有 BRVO，18 名患者患有 CRVO。
所有患者的随访时间均不少于 12 个月。所有患者在就诊时均行眼底荧光素血管造影（FFA）和光学相干断层扫描（OCT）检查。RVO 发生与初次检查和治疗之间的时间间隔<1 个月。所有患者均接受 2 次连续的玻璃体内雷珠单抗（0.5mg）注射，间隔 1 个月。根据 OCT 结果，每月进行评估，如果有必要则进行注射。
BRVO 组中有 13 名患者（13/22，59%）发生 ME 复发，而 CRVO 组中所有患者（18/18，100%）均发生 ME 复发。BRVO 和 CRVO 组从最后一次注射到复发的平均时间间隔分别为 2.4 个月和 1.2 个月。BRVO 组 ME 吸收的平均时间为 2.5 个月，CRVO 组为 3.5 个月。
我们的患者中有 77.5%发生了复发性 ME。这些复发在 CRVO 患者中更早出现、更明显且持续时间更长。
Zotero 插件